Statistics from Altmetric.com
We thank Dr James for offering further comments on the debate on estimating deaths due to medical error, and for his clarification of the definition used in his Journal of Patient Safety article.1 Dr James' letter reinforces the need for improved consistency, explicitness and reproducibility in measurement of medical error (and harms associated with it) that we called for in our article.2
One area where such clarity is much needed is in what Dr James describes as errors of omission, which by their nature are more difficult to detect than the slips and lapses that have traditionally been the concern of patient safety efforts. He mentions the example of β-blockers as a treatment for patients with heart failure, but this is not a straightforward example of deficient practice. While it is true that some early studies in the 1980s suggested a positive impact, β-blockers did not become widely recommended for heart failure until the 1990s because it continued to be an area of controversy until the evidence had become more firmly established. And, though β-blockers did go on to become standard treatment of heart failure, the much-touted use of perioperative β-blockers—which became a widely commended patient safety practice based on early trials—did not. In fact, perioperative β-blockers were associated with harm.3
These twists and turns in the evidence base are often the norm in healthcare. In consequence, while it may appear in hindsight that early studies should have changed practice, the results of early trials are often not replicated or they are even overturned in real time.4 ,5 One survival analysis found that an important change in a result or recommendation occurred for 57% of 100 systematic reviews (95% CI 47% to 67%);6 median duration of survival free of a signal for updating was 5.5 years (CI 4.6 to 7.6 years). However, a signal occurred within 2 years for 23% of reviews and within 1 year for 15%. In 7%, a signal had already occurred at the time of publication.
A further challenge with identifying errors of omission is that it risks making any under-use of evidence-based therapy into a safety problem. Among other things, it runs into the definitional problem that identifying a time after which the failure to use some therapy should be regarded as an error is not easy, and may not adequately account for the role of patient preference or well-informed clinical judgement in choices about such therapies.
Not everyone will agree with these points. That is fine: legitimate disagreement is the hallmark of a healthy scientific field. What is not fine is allowing a failure to reach consensus to blight the field, and in particular to damage the endeavour of quantifying rates of avoidable harm. We fully support Dr James' call for development of a consensus definition.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.